SAN FRANCISCO, CA--(Marketwired - December 22, 2015) - In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
Included in this interview are: Asterias Biotherapeutics Inc. (
Nineteen companies have made the cut for inclusion in the 2016 Small-Cap Biotech Watchlist, now in its fourth year. The therapies under development address diverse indications, such as rare diseases, ophthalmological conditions, leg cramps, kidney disease, infections caused by catheters, and a number of cancers, with a variety of products, including traditional biologics, cell therapies and vaccines.
The panelists who selected the 2016 Small-Cap Biotech Watchlist are George Zavoico of JonesTrading International Services, Mara Goldstein of Cantor Fitzgerald, Reni Benjamin of Raymond James, Ragharum (Ram) Selvaraju of Rodman and Renshaw, and Mike King of JMP Securities. Each selected four names for the list; one company got…
Continue reading this interview: Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Asterias Biotherapeutics Inc. and CorMedix Inc. are sponsors of Streetwise Reports. Pieris Pharmaceuticals Inc. and Peregrine Pharmaceuticals paid Streetwise Reports to distribute. Reni Benjamin, Mara Goldstein, Michael King, Raghuram Selvaraju and George Zavoico had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Benjamin, Ms. Goldstein, Mr. King, Mr. Selvaraju and Mr. Zavoico and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Contact Information:
Contact:
Jim Patrick